Home
Scholarly Works
Data from SALVO: Single Arm Trial of Ipilimumab...
Other

Data from SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma

Abstract

<div>Abstract<p>Background: Mucosal melanoma is a rare, aggressive form of melanoma with extremely high recurrence rates despite definitive surgical resection with curative intent. Currently there is no consensus on adjuvant therapy. Data on checkpoint inhibitors (CPI) for adjuvant therapy is lacking. Methods: We performed a single arm, multicenter clinical trial using “flip dose” ipilimumab (1mg/kg q3w x4 cycles), and nivolumab (3 mg/kg q3w x4 cycles), then Nivolumab 480 mg q4w x 11 cycles to complete a year of adjuvant therapy. Participants must have had R0/R1 resection <90 days prior to registration, no prior systemic therapy (adjuvant radiation allowed), ECOG 0/1, no uncontrolled autoimmune disease or other invasive cancer. Patients were recruited through the Midwest Melanoma Partnership/Hoosier Oncology Network. Results: From Sept 2017 to August 2021 35 patients enrolled. Of these, 29 (83%) had R0 resections, and 7 (20%) received adjuvant radiation. Median age was 67 years, 21 (60.0%) female. Relapse-free survival rates at 1 and 2 years were 50% (95% CI 31-66%) and 37% (95% CI 19-55%), respectively. Overall survival rates at 1 and 2 years were 87% (95% CI 68-95%) and 68% (95% CI 46-83%), respectively. Median RFS was 14.3 m (95% CI 5.7-25.8). Most common grade 3 toxicities were diarrhea (14%), hypertension (14%), and hyponatremia (11%), with no grade 4/5 toxicities. Conclusions: Flip dose ipilimumab and nivolumab after resection of mucosal melanoma is associated with outcomes improved over that of surgical resection alone. Long term follow up, subgroup analyses and correlative studies are ongoing.</p></div>

Authors

Kottschade LA; Pond GR; Olszanski AJ; Zakharia Y; Domingo-Musibay E; Hauke RJ; Curti BD; Schober S; Milhem MM; Block MS

Publication Date

September 16, 2024

DOI

10.1158/1078-0432.c.6615932.v3
View published work (Non-McMaster Users)

Contact the Experts team